Aspirin after preeclampsia: could a simple pill protect Women's hearts?
NCT ID NCT06168461
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Women who had preeclampsia are four times more likely to develop heart disease later in life, possibly due to lasting blood vessel damage. This early-phase trial tests whether taking low-dose aspirin (162 mg daily) can improve blood vessel function in 40 women who had preeclampsia within the past five years. Researchers will measure how well blood vessels respond to certain signals, comparing aspirin to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin
What this could lead to
If it works, this could point toward a simple, low-cost treatment to lower heart disease risk in women who had preeclampsia.
What could go wrong
This is a very early, small trial (40 people) testing short-term effects on blood vessel function, not long-term heart health. Aspirin may not provide lasting benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••